Bod Australia becomes one of the first ASX listed companies to...

Bod Australia becomes one of the first ASX listed companies
to be granted a medicinal cannabis import licence.
 Import licence granted for medicinal cannabis products
 Licence will allow the import of Linnea’s unique phyto-complex cannabis extracts for multiple
commercial and clinical applications
 Key catalyst for sale of finished goods and commencement of Phase I Clinical trials
Sydney, Australia – 4 December 2017: Developer and distributor of natural, evidence-based cosmetics and
natural medicines Bod Australia Limited (“Bod” or the “Company”) (ASX: BDA) is pleased to advise that it has
been granted an import licence for medicinal cannabis products.
The licence, granted through the NSW Department of Health and the Therapeutic Goods Administration, allows
for the, storage and supply of medicinal cannabis. Following permission to import from the Office of Drug
Control (ODC), Product will be available to authorised prescribers and for Bod’s clinical trial programs. According
to the ODC website Bod is one of the first ASX listed companies to be granted a licence to import medicinal
cannabis.
Bod will now begin the process for approval through the Federal ODC to import a range of cannabis products
from overseas producers including oils and raw materials from exclusive partner, Linnea SA. This will be in the
form of finished goods for immediate commercial purposes and for use in clinical trials.
Linnea is a manufacturer of medicinal cannabis extracts, botanical and pharmaceutical ingredients and finished
goods for use in the pharmaceutical, nutraceutical and cosmetic industries. Based in Switzerland, Linnea has
been operating for over 35 years and is owned by two large European companies – Ipsen and Schwabe.
Linnea’s industry-leading standardised phyto-complex cannabis extracts are internationally renowned for having
very low THC concentrations (less than 0.05%). In addition, Linnea are able to preserve the cannabinoid and
phytocomplex profiles of the plant – producing a unique extract that has a standardised and consistent chemical
profile.
This is a significant and material development for Bod and marks a key step in the Company establishing their
medicinal cannabis operations in Australia and growing revenues from the sale of the therapeutic goods and
extracts.
The Company expects to generate near term revenues from the sales of cannabis oils, which will be available for
patients through physicians authorised to prescribe medicinal cannabis under Special Access Category B. There
are currently a growing number of physicians licenced to prescribe medicinal cannabis in Australia and Bod looks
forward to working with them in the future.
Further to receiving the licence and relative approvals, the Company will finalise a product for their Phase I
Clinical trial scheduled to begin in 2018. The Phase I trial aims to assess the safety, tolerability and
pharmacokinetics of a proprietary sublingual formulation of the unique Linnea phytocomplex cannabis extract.
The results of this trial will assist to lead to the development of specific therapeutic indications for Bod’s
medicinal cannabis product suite. The Company is currently finalising the Phase I Clinical trial program and will
update shareholders on these developments shortly.
In addition, the licence and related research trials enable Bod to develop cannabis based products and materials
for potential export markets in Asia as part of a broader distribution strategy.
Bod Australia CEO Jo Patterson said: “Receiving an import licence is a great achievement for Bod Australia and
delivers significant value. It is a game changer in establishing medicinal cannabis operations in Australia.
“In order to move to an environment which we generate sales from this part of our business, we will sell our
Cannabis Oil through approved prescribers under the Special Access Category B scheme. We will also commence
our research and development to develop a unique product for our clinical trials.
“The Company is currently investigating ways in which we can advance our Phase I Clinical Trial design to reduce
time to market and cost savings, and look forward to updating shareholders as this progresses. We are also
undertaking discussions around the production of a patented and unique delivery method for our trial and are
pleased to say that these are well advanced. We anticipate further updates on this front in the near future.”
For more information: bodaustralia.com
- ENDS -